Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN) by De Angelis M. et al.
Microbiota and Metabolome Associated with
Immunoglobulin A Nephropathy (IgAN)
Maria De Angelis1*, Eustacchio Montemurno2, Maria Piccolo1, Lucia Vannini3, Gabriella Lauriero2,
Valentina Maranzano2, Giorgia Gozzi3, Diana Serrazanetti4, Giuseppe Dalfino2, Marco Gobbetti1,
Loreto Gesualdo2
1 Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, Bari, Italy, 2 Department of Emergency and Organ Transplantation, Nephrology Unit -
University of Bari Aldo Moro, Bari, Italy, 3 Department of Agricultural and Food Sciences, University of Bologna, Bologna, Italy, 4 Inter-departmental Centre for Industrial
Agri-Food Research, University of Cesena, Cesena, Italy
Abstract
This study aimed at investigating the fecal microbiota, and the fecal and urinary metabolome of non progressor (NP) and
progressor (P) patients with immunoglobulin A nephropathy (IgAN). Three groups of volunteers were included in the study:
(i) sixteen IgAN NP patients; (ii) sixteen IgAN P patients; and (iii) sixteen healthy control (HC) subjects, without known
diseases. Selective media were used to determine the main cultivable bacterial groups. Bacterial tag-encoded FLX-titanium
amplicon pyrosequencing of the 16S rDNA and 16S rRNA was carried out to determine total and metabolically active
bacteria, respectively. Biochrom 30 series amino acid analyzer and gas-chromatography mass spectrometry/solid-phase
microextraction (GC-MS/SPME) analyses were mainly carried out for metabolomic analyses. As estimated by rarefaction,
Chao and Shannon diversity index, the lowest microbial diversity was found in P patients. Firmicutes increased in the fecal
samples of NP and, especially, P patients due to the higher percentages of some genera/species of Ruminococcaceae,
Lachnospiraceae, Eubacteriaceae and Streptococcaeae. With a few exceptions, species of Clostridium, Enterococcus and
Lactobacillus genera were found at the highest levels in HC. Bacteroidaceae, Porphyromonadaceae, Prevotellaceae and
Rikenellaceae families differed among NP, P and HC subjects. Sutterellaceae and Enterobacteriaceae species were almost
the highest in the fecal samples of NP and/or P patients. Compared to HC subjects, Bifidobacterium species decreased in the
fecal samples of NP and P. As shown by multivariate statistical analyses, the levels of metabolites (free amino acids and
organic volatile compounds) from fecal and urinary samples markedly differentiated NP and, especially, P patients.
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Introduction
Immunoglobulin A nephropathy (IgAN), also defined as
mesangial IgA glomerulonephritis, is characterized by dominant
mesangial IgA deposition. IgAN was first described by Berger in
1968 [1], and it is the most common primary glomerulonephritis
worldwide [2,3]. The prevalence of IgA nephropathy observed in
renal biopsy registries is estimated to be 5% in the US, 10–20% in
Europe and Australia, and 30–40% in Asia. Although it is a rather
benign disorder in many patients, long-term studies showed that
25% to 50% of IgAN patients develop the end-stage kidney disease
(ESKD) due to the progressive formation of IgA immune
complexes (IgA-ICs) [4,5,6,7,8]. Although IgA-IC formation is
thought to be universal in IgAN, clinical features, biopsy findings,
and disease progression are highly variable. Patients in whom
IgAN runs a benign course, the non progressors (NP), cannot
currently be identified from progressors (P) at diagnosis [9].
Recently, IgAN patients were classified as non progressor (NP)
when they fulfilled both the following criteria: (i) decrease, after at
least 6 months, in daily proteinuria 50% of the value recorded at
the start of therapy with Angiotensin-converting enzyme inhibitors
(ACEi) treatment; and (ii) stable glomerular filtration rate
throughout ACEi treatment [10,11]. The IgAN pathogenesis is
still unknown, and, even though under investigation, no specific
treatments to stop the progression toward ESKD are currently
available [12]. Hyper-production of poorly galactosylated IgA1 is
thought to play a role in the primary IgAN [13]. The knowledge of
downstream effector mechanisms, which are triggered by mesan-
gial IgA1 deposition, is rather poor [14]. Genome-wide association
studies (GWAS) identified multiple susceptibility loci IgAN, which
implies independent defects of adaptive immunity (MHC region of
the chromosome 6p21), innate immunity (8p23 DEFA, 17p23
TNFSF13 and 22q12 HORMAD2 loci) and alternative comple-
ment pathway (1q32 CFH/CFHR locus) [15]. Recently, it was
shown the induction of glomerulonephritis by IgA rheumatoid
factors [16]. Besides, the balance of various factors at the mucosal
microenvironment level plays an important role in regulating the
synthesis of IgA [17]. A presumptive role of the intestinal
microbiota in educating the immune system and IgAN disease
development was shown in B cell activation factor of the TNF
family overexpressing trans-genic (BAFF-Tg) mice [14].
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Overall, human microbiota contains 1014 bacterial cells, a
number that is 10 times higher than the number of human body
cells [18]. The human intestine is particularly dense of microbes,
1012 bacteria per g (dry weight), especially at colon level. The
intestinal ecosystem is in part responsible for maintaining human
health. It is involved in the protection against pathogens,
education of the immune system and modulation of gastrointes-
tinal development. Intestinal microbes play a pivotal role or
contribute to many diseases. Alterations of the composition of the
intestinal microbiota are associated with inflammatory bowel
diseases (IBD), irritable bowel syndrome and allergic diseases
[18,19,20,21]. Differences on the composition of the intestinal
microbiota are also linked to Type 1 and Type 2 diabetes [22],
celiac disease (CD) [23,24], autism [25], liver disease [26] and
minimal hepatic encephalopathy (MHE) [27]. Under healthy
conditions, the human microbiota provides trophic and protective
functions. Nevertheless, uremia per se and therapeutic treatments
of ESKD (i.e., phosphate binders, diet restriction) may lead to
modifications of the composition and metabolic activities of the
intestinal microbiota [28]. Recently, it was hypotized that the
manipulation of the microbiota can be a strategy for the gastro-
intestinal diseases [29,30,31]. Previously, it was shown that
patients with ESKD had a marked increase of Brachybacterium
and Catenibacterium genera, and Enterobacteriaceae, Halomonada-
ceae, Moraxellaceae, Nesterenkonia, Polyangiaceae, Pseudomo-
nadaceae, and Thiothrix families within the intestinal microbiota
[28,32]. Despite of the considerable investigation of the biochem-
ical abnormalities of IgA1, the composition and metabolic activity
of human intestinal microbiota in IgAN patients were poorly
considered. Signaling induced by TNF family members BAFF was
implicated in the IgAN pathogenesis of BAFF-Tg mice [14].
Besides, BAFF-Tg mice developed commensal bacteria-IgA
associated nephropathy. This evidence might support the role of
the intestinal microbiota in the gut-kidney axis.
This study aimed to comparing IgAN patients (NP and P) and
healthy controls (HC) based on fecal microbiota, and urinary and
fecal metabolome. Total and active fecal microbiota was analyzed
through an integrate approach of culture-dependent and -
independent methods, and metabolomic analyses. Bacterial tag-
encoded FLX-titanium amplicon pyrosequencing (bTEFAP) and
gas-chromatography mass spectrometry/solid-phase microextrac-
tion (GC-MS/SPME) analyses were mainly carried out for
genomic and metabolomic analyses.
Materials and Methods
Study design
The study was carried out in accordance with the Helsinki
Declaration (IV Adaptation) and European Guidelines for Good
Clinical Practice. The protocol of the study was approved by the
Institutional Review Board of Azienda Ospedaliero-Universitaria
Consorziale Policlinico of Bari, Italy. Written consents were
obtained from all subjects. Volunteers were enrolled at the out-
patient setting of the ‘‘Division of Nephrology, Dialysis and
Transplant, Policlinico Hospital’’ of Bari, Italy. Three groups of
caucasian volunteers were included in the study: (i) sixteen IgAN
NP patients (subjects numbered: 1 – 16 NP); (ii) sixteen IgAN P
patients (subjects numbered: 1 – 16 P); and (iii) sixteen healthy
control (HC) subjects, without known diseases (subjects numbered:
1 – 16 HC). HC group included healthy subjects matched to cases
on age and gender. Exclusion criteria included the presence of
type 1 or type 2 diabetes mellitus, neurological or gastro-intestinal
diseases, acute myocardial infarction or stroke in the previous 6
months, severe uncontrolled hypertension (diastolic blood pressure
$120 mmHg and/or systolic blood pressure $220 mmHg),
evidence or suspicion of renovascular disease, severe liver diseases,
malignancies, active peptic-ulcer disease, secondary IgAN or
relapse in renal allograft, renal allograft; pregnancy, others
immunological or autoimmune disorders, alcohol abuse, psychi-
atric disease and inability to assess the follow-up. Subjects included
in the study were not treated with antibiotics and/or functional
foods (probiotics and/or prebiotics) for at least three months
before sampling. All volunteers confirmed that there were no
remarkable changes in meals and medication for at least 1 month.
We evaluated serum creatinine, urine protein, glomerular
filtration rate (MDRD GFR) and Body Mass Index at baseline
and after six months of follow up (Table 1). In addition, renal
biopsy specimens of all IgAN patients were classified according to
Oxford Classification which identify four pathological features
(mesangial hypercellularity M, endocapillary hypercellularity E,
segmental glomerulosclerosis S, and tubular atrophy/interstitial
fibrosis T, resulting in a MEST score). After six months, as
described by Rocchetti et al. [11], patients were classified as NP
and P according to their proteinuria and renal function. In detail,
IgAN NP patients showed a 50% decrease in daily proteinuria and
a stable renal function (eGFR) when compared with baseline. For
HC, dipstick urine analysis (Combur-Test, Boehringer Mannheim
GmbH, Mannheim, Germany) was carried out (Table 1).
Collection of fecal and urine samples
Each volunteer provided three fecal and urinary samples for a
time span of three weeks. Each volunteer had fasted overnight,
and fecal sample was collected in the morning pre-prandial. Urine
samples were collected after the second mittus into sterile
collection cups. After collection, in sterile plastic box, feces were
immediately mixed with RNA later (Sigma-Aldrich, St. Louis,
MO, USA) (5 g, 1:2 w/v) or with Amies Transport medium
(Oxoid LTD, Basingstoke, Hampshire, England) (15 g, 1:1 w/w),
under anaerobic conditions (AnaeroGen, Oxoid LTD). Fecal
samples suspended in RNA later were stored at 280uC for further
DNA and RNA analyses. Samples diluted with Amies Transport
medium were immediately subjected to culture-dependent (plate
counts) and metabolome analyses. Three urine aliquots per each
subject were immediately frozen and stored at 280uC until use.
Enumeration of cultivable bacteria
Diluted fecal samples (20 g) were mixed with 80 ml sterilized
physiological solution and homogenized. Counts of viable
bacterial cell were carried out as described by Francavilla et al.
[20]. The following selective media were used: Plate count agar
(total facultative aerobes and anaerobes); MRS agar (lactobacilli
and enterococci); Bifidobacterium agar modified (bifidobacteria)
(Becton Dickinson France SA, Le Pont de Claix, France); M17
(lactococci and streptococci); Mannitol salt agar (stafilococci);
Wilkins-Chalgren anaerobe agar (total anaerobes); Wilkins-Chalg-
ren anaerobe agar plus GN selective supplements and sheep blood
defibrinated (Bacteroides, Porphyromonas and Prevotella); Reinforced
Clostridial Medium supplemented with 8 mg/L novobiocin,
8 mg/L colistin (Clostridium); MacConkey agar No2 (Enterobacte-
ria); Rogosa agar plus 1.32 mL/L of glacial acetic acid (lactoba-
cilli); GSP agar (Fluka) plus penicillin-G (60 g/L) (Pseudomonas,
Aeromonas); and Slanetz and Bartley (enterococci). Except for
Bifidobacterium agar modified and GSP agar, all media were
purchased by Oxoid Ltd (Hampshire, England).
DNA extraction from fecal samples
After homogenization with RNA later, fecal samples were
mixed 1:1 with distilled water in sterile plastic pestle. The
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homogenate was subjected to mechanical disruption with the
FastPrep instrument (BIO 101) and total DNA was extracted with
the FastDNA Spin Kit for Soil (MP Biomedicals, Illkrich, France),
according to the manufacturer’s instructions. An aliquot of about
300 mL of each fecal sample was diluted in 1 mL of PBS-EDTA
(phosphate buffer 0.01 M, pH 7.2, 0.01 M EDTA). After centri-
fugation (14,0006g at 4uC for 5 min), the pellet was washed two
times to decrease the content of PCR inhibitors. The resulting
pellet was re-suspended into 300 mL of PBS-EDTA and used for
DNA extraction with the FastPrep. The product was consisting of
50–100 mL of application-ready DNA. Quality and concentration
of DNA extracts were determined using 1% agarose-0.5X TBE
gels, which were stained with Gel Red 10,000X (Biotium, Inc.)
and analyzed through spectrophotometric measurements at 260,
280 and 230 nm, using the NanoDrop ND-1000 Spectrophotom-
eter (ThermoFisher Scientific Inc., MI, Italy).
RNA extraction from fecal samples
An aliquot of 200 mg of fecal sample diluted in RNA later was
used for RNA extraction with the Stool total RNA purification kit
(Norgen, Thorold, TO). Total RNA was treated with RNase-free
DNase I (Roche, Almere, Netherlands; 10 U of DNase per 20 mg
of RNA) for 20 min at room temperature. Quality and concen-
tration of RNA extracts were determined using 1% agarose-0.5X
TBE gels and spectrophotometric measurements at 260, 280 and
230 nm through the NanoDrop ND-1000 Spectrophotometer.
Total RNA extracted (2.5 mg) was retrotranscribed to cDNA using
random examers and the Tetro cDNA synthesis kit from Bioline
(Bioline, Freiburg, Germany), according to the manufacturer’s
instructions [33].
Bacterial tag-encoded FLX amplicon pyrosequencing
(bTEFAP) and data analyses
For each subject, the three DNA or cDNA samples, which
corresponded to as any samplings, were pooled and used for
bTEFAP analysis. bTEFAP was performed by Research and
Testing Laboratories (Lubbock, TX), according to standard
laboratory procedures and using the 454 FLX Sequencer (454
Life Sciences, Branford, CT). Samples were amplified for bTEFAP
using a forward and reverse fusion primer. The forward primer
was constructed with (59–39) the Roche A linker (CCATCT-
CATCCCTGCGTGTCTCCGACTCAG), an 8–10 bp barcode,
and the forward 28F: GAGTTTGATCNTGGCTCAG primer
[34]. The reverse fusion primer was constructed with (59–39) a
biotin molecule, the Roche B linker (CCTATCCCCTGT-
GTGCCTTGGCAGTCTCAG), and reverse 519R GTNTTA-
CNGCGGCKGCTG. Primers 28F and 519R are based upon the
V1–V3 region (Escherichia coli position 27–519) of the 16S rRNA
gene [34]. Amplifications were performed in 25 ml reactions with
Qiagen HotStar Taq master mix (Qiagen Inc, Valencia,
California), 1 ml of each 5 mM primer, and 1 ml of template.
Reactions were performed on ABI Veriti thermocyclers (Applied
Biosytems, Carlsbad, California) under the following thermal
profile: 95uC for 5 min, then 35 cycles of 94uC for 30 sec, 54uC
for 40 sec, 72uC for 1 min, followed by one cycle of 72uC for
10 min and 4uC hold. Amplification products were visualized with
eGels (Life Technologies, Grand Island, NY). Products were then
pooled equimolar and each pool was cleaned with Diffinity
RapidTip (Diffinity Genomics, West Henrietta, NY), and size
selected using Agencourt AMPure XP (BeckmanCoulter, India-
napolis, Indiana) following Roche 454 protocols (454 Life
Sciences, Branford, Connecticut). Size selected pools were then
quantified and 150 ng of DNA were hybridized to Dynabeads M-
270 (Life Technologies) to create single stranded DNA following
Roche 454 protocols (454 Life Sciences). Raw sequence data were
screened, trimmed and filtered with default settings, using the
QIIME pipeline version 1.4.0 (http://qiime.sourceforge.net).
Chimeras were excluded by using the B2C2 (http://www.
researchandtesting.com/B2C2.html) [35]. Sequences less than
250-bp were removed. Sample sets yielded 320,012 and 192,374
bacterial 16S rDNA and 16S rRNA gene sequences, respectively.
After quality control, pyrosequencing analysis yielded an average
of 8,355 reads sequences (average length 394-bp) per sample.
Sequences that pass the quality control screening were condensed
into a single FASTA formatted sequence and quality file such that
each read has a one line descriptor followed by a single line of
sequence/quality data. The descriptor line in both files has been
altered to contain the samples name followed by the original
descriptor line, separated with a unique delimiter (::). FASTA
sequences for each sample, without chimeras, were evaluated
using BLASTn against a database derived from GenBank (http://
ncbi.nlm.nih.gov) [36].
Taxonomic identification
The sequences were first clustered into Operational Taxonomic
Unit (OTU) clusters with 97% identity (3% divergence), using
USEARCH [37]. For each cluster the seed sequence was placed in
a FASTA formatted file. To determine the identities of bacteria,
sequences were first queried using a distributed BLASTn. NET
algorithm [36] against a database of high-quality 16S bacterial
sequences that derived from NCBI. Database sequences were
characterized as high quality based on criteria, which were
originally described by Ribosomal Database Project (RDP, v10.28)
[38]. Using a NET and C# analysis pipeline, the resulting
BLASTn outputs were compiled and validated using taxonomic
distance methods, and data reduction analysis was performed as
described previously [39]. Based on the above BLASTn derived
sequence identity percentage, the sequences were resolved at the
appropriate taxonomic levels as follows: $97% (,3% divergence),
species level (OTUs); 95 – 97%, genus; 90 – 95%, family; 85 –
90%, order; 80 – 85%, class; and 77 – 80%, phyla. Any match
below this identity levels was discarded. The percentage of each
bacterial identification (ID) was individually analyzed for each
fecal sample, providing relative abundance information on relative
numbers of reads within a given sample. Divergences of 3 and 5%
were indicative of sequences, which differed at species and genus
levels, respectively. The student’s t-test results seen in Table 2
indicate significantly lower diversity levels in NP and P when
compared to HC. Alpha diversity (rarefaction, Good’s coverage,
Chao1 richness and Shannon diversity indices) and beta diversity
measures were calculated and plotted using QIIME [34,40,41].
Final datasets at species and other relevant taxonomy levels were
compiled into separate worksheets for compositional analysis
among the three groups of subjects [42]. Differences in microbial
communities between NP, P and HC groups were also investigated
using the phylogeny-based unweighted Unifrac distance metric
[34].
Fecal concentration of free amino acids
Total and individual free amino acids (FAA) of fecal samples
were analyzed through the Biochrom 30 series amino acid
analyzer (Biochrom Ltd., Cambridge Science Park, England) with
a sodium cation-exchange column (20 by 0.46 cm [inner
diameter]). A mixture of amino acids at known concentrations
(Sigma Chemical Co., Milan, Italy) was added with cysteic acid,
methionine sulfoxide, methionine sulfone, tryptophan, ornithine,
glutamic acid, and c-amino-butyric acid (GABA) and used as
standard. Proteins and peptides in the samples were precipitated
Microbiota and Metabolome of IgA Nephropathy Patients
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by addition of 5% (v/v) cold solid sulfosalicylic acid, holding the
samples at 4uC for 1 h, and centrifuged them at 15,0006g for
15 min. The supernatant was filtered through a 0.22- mm-pore-
size filter and when necessary diluted, with sodium citrate (0.2 M,
pH 2.2) loading buffer. Amino acids were post-column derivatized
with ninhydrin reagent and detected by absorbance at 440 (proline
and hydroxyproline) or 570 (all the other amino acids) nm.
Gas-chromatography mass spectrometry-solid-phase
microextraction (GC-MS/SPME) analysis of fecal and
urinary volatile compounds
After preconditioning, according to the manufacturer’s instruc-
tions, a polydimethylsiloxane/Divinylbenzene fiber (PDMS/DVB)
(65 mm) and a manual solid phase micro-extraction (SPME) holder
(Supelco Inc., Bellefonte, PA) were used. Before headspace
sampling, the fiber was exposed to GC inlet for 5 min for thermal
desorption at 250uC. Three grams of fecal sample were placed into
10 mL glass vials and added of 10 mL of 4-methyl-2-pentanol (final
concentration of 33 mg/L), as the internal standard. Samples were
then equilibrated for 10 min at 40uC. SPME fiber was exposed to
each sample for 40 min. Both equilibration and absorption phases
were carried out with stirring. The fiber was then inserted into the
injection port of the gas chromatograph for 10 min of sample
desorption. GC-MS analyses were carried out with an Agilent
7890A gas chromatograph (Agilent Technologies, Palo Alto, CA)
coupled to an Agilent 5975C mass selective detector operating in
an electron impact mode (ionization voltage, 70 eV). A Supelco-
wax 10 capillary column (length, 60 m; inside diameter, 0.32 mm;
Supelco, Bellefonte, PA) was used. The temperature program was
50uC for 1 min, followed by an increase, at a rate of 4.5uC/min, to
65uC, an increase, at a rate of 10uC/min, to 230uC, and then
230uC for 25 min. The injector, interface and ion source
temperatures were 250, 250, and 230uC, respectively. The mass-
to-charge ratio interval was 30 to 350 Da at a rate of 2.9 scans per
s. Injection was carried out in splitless mode, and helium (flow rate,
1 mL/min) was used as the carrier gas. Molecule identification
was based on comparison of their retention times with those of
pure compounds (Sigma-Aldrich, Milan, Italy). Identities were
confirmed by searching mass spectra in the available databases
(NIST, version 2005; Wiley, version 1996). All the GC-MS raw
files were converted to netCDF format via Chemstation (Agilent
Technologies) and subsequently processed with the XCMS
toolbox (http://metlin.scripps.edu/download/). XCMS software
allows automatic and simultaneous retention time alignment,
matched filtration, peak detection and peak matching. The
resulting table containing information such as peak index
(retention time-m/z pair) and normalized peak area was exported
into R (www.r-project.org) for subsequent statistical or multivar-
iate analyses [43]. Quantitative data for the compounds identified
were obtained by the interpolation of the relative areas versus the
internal standard area [44]. GC-MS/SPME data were organized
into matrix and analyzed by Canonical discriminant Analysis of
Principal coordinates [24].
Statistical analysis
bTEFAP data (Unifrac distance metric and taxonomic abun-
dance) were analyzed by Principal Component Analysis (PCA) to
assess the bacterial composition of samples [42,45], using the
statistical software Statistica for Windows (Statistica 6.0 per
Windows 1998, (StatSoft, Vigonza, Italia). Variables (features)
are the relative bacterial composition in the sample at a particular
taxonomic level [42]. In addition, the Permut-MatrixEN software
was used to identify clusters at the level of the NP, P and HC
groups and taxa [46]. Culture dependent and metabolomics data
were obtained at least in triplicates. The analysis of variance
(ANOVA) was carried out on transformed data followed by
separation of means with Tukey’s HSD, using the statistical
software Statistica for Windows (Statistica 6.0 per Windows 1998,
(StatSoft)). Letters indicate significant different groups (P,0.05) by
Tukey’s test. Canonical discriminant Analysis of Principal
coordinates (CAP) analysis was also carried out for GC-MS/
SPME data [44]. The hypothesis of not significant differences in
the multivariate location within groups was tested using the trace
statistic based on 9999 permutations [44].
Results
Enumeration of fecal cultivable bacteria
Compared to HC, the number of heterotrophic aerobic and
anaerobic bacteria significantly (P,0.05) decreased in the fecal
samples of NP and P patients (Figure 1). Total presumptive
Clostridium were the highest in HC. P patients showed median
values of presumptive Enterococcus, Lactobacillus and Leuconostoc lower
than those found for HC and NP. No statistical differences (P.
0.05) were found between NP, P and HC for presumptive
Table 2. Pyrosequencing data summary.
HC group NP group P group
16S rDNA
OTUs (species) 284612.0a 232611.3b 206610.4c
Chao1 809642.1a 738631.8b 689635.6c
Shannon index 5.1360.16a 4.8760.04b 4.5260.11b
Good’s coverage 98.3661.02 98.4561.87 97.1661.93
16S rRNA
OTUs (species) 256613.08a 233614.37b 214617.20c
Chao1 782640.27a 717638.01b 643626.84c
Shannon index 5.0260.03a 4.6160.05b 4.3860.07c
Good’s coverage 97.4562.09 97.2861.54 98.0361.70
HC, healthy controls;NP, Immunoglobulin A nephropathy (IgAN) non-progressor; P, IgAN progressor; 16S rDNA, total bacteria; 16S rRNA, metabolically active bacteria.
a–cValues within a row with different superscript letters are significantly different (P,0.05).
doi:10.1371/journal.pone.0099006.t002
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Lactococcus, Streptococcus, Staphylococcus, Bacteroides and Enterobacte-
riaceae. Compared to HC, significantly (P,0.05) lower counts of
presumptive Bifidobacterium were found in the fecal samples of NP
and, especially, P patients.
Pyrosequencing analysis of the fecal community of
bacteria
Total and metabolically active bacteria from fecal samples of
NP and P patients and HC subjects were analyzed by pyrose-
quencing of 16S rDNA and rRNA genes, respectively. The
bacterial community was analyzed by rarefaction curves, species
level (OTUs) richness estimator (Chao1) and diversity index
(Shannon) (Table 3). The average number of OTUs indicated
differences between fecal samples of NP and P compared to HC.
Eight bacterial phyla were identified in NP, P and HC subjects
(Figure 2 and 3). Firmicutes, Bacteroidetes, Proteobacteria and
Actinobacteria represented more than 98% of all 16S rDNA and
16S rRNA gene sequences (Figure 2 and Figure S1). Overall,
different values were found between total (16S rDNA analysis)
(Figure 2 and S1A) and metabolically active phyla (16S rRNA
analysis) (Figure 2 and S1B). No significant (P.0.05) differences
were found for total Firmicutes between NP, P and HC (83.07,
83.05 and 80.09%, respectively) (Figure 2 and S1A). Compared to
HC (60.13%), metabolically active Firmicutes increased in NP
(68.20%) and P (67.42%) patients (Figure 2 and S1B). An opposite
trend was found for Bacteroidetes, which showed the highest value
in HC in both 16S rDNA and 16S rRNA analyses (Figure 2 and
and S1). Total and metabolically active Proteobacteria and
Actinobacteria were, respectively, the lowest and the highest in
HC.
Distinctive core microbiome associated with IgAN
Compared to HC and NP, total (16S rDNA analysis)
Streptococcaceae (phylum Firmicutes), markedly increased (P,
0.05) in P patients and reached the 11.54% of the total 16S rDNA
reads (Figure S1A). Eubacteriaceae family was higher in P
Figure 1. Fecal cultivable bacteria of the main microbial groups. Cultivable cells (log cfu/g) found in the fecal samples of immunoglobulin A
nephropathy (IgAN) non progressor (NP) and progressor (P) patients, and healthy controls (HC). Data are the means of three independent
experiments (n = 3). The top and bottom of the box represent the 75th and 25th percentile of the data, respectively. The top and bottom of the error
bars represent the 5th and 95th percentile of the data, respectively. #, Outliers data. Group student’s t-test p-values were also shown.
doi:10.1371/journal.pone.0099006.g001
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compared to HC (Figure S1A–B). Lactobacillaceae was the lowest
(P,0.05) in P patients. Within Bacteroidetes phylum, Bacteroida-
ceae and Prevotellaceae families were the lowest (P,0.05) in P and
NP patients, respectively. Within the Proteobacteria, Alcaligen-
aceae and Enterobacteriaceae families increased (P,0.05) in P
patients. Compared to HC, Bifidobacteriaceae (phylum Actino-
bacteria), markedly decreased (P,0.05) in NP and, especially, in P
patients. At 16S rDNA level, Coriobacteriaceae increased in NP
and P compared to HC. Differences in the relative abundance
between total and metabolically active bacterial families were
highlighted by permutation analyses (Figure S2). Overall, the
highest similarity was found between HC and NP for total
bacterial families, and between NP and P for metabolically active
families.
Using genus composition data, 223 and 192 genera were found
by 16S rDNA and rRNA analyses, respectively. Unifrac distance
metric and taxonomic abundance at genus level were further
analyzed by PCA. As shown in the 3-D plot (Figure 4), no
systematic differences were found among 16S rDNA sequences,
which were associated to the three groups. On the contrary, fecal
samples of NP, P and HC were clustered in different zone of the 3-
D plot when the 16S rRNA sequences were analyzed (Figure 5).
Based on this finding and considering that only metabolically
active bacteria give a general picture of the microbial activities at
Figure 2. Total and active bacteria found in feces of subjects. Relative abundance (%) of total (16S rDNA) and metabolically active (16S rRNA)
bacteria, which were found at the phylum level in the fecal samples of immunoglobulin A nephropathy (IgAN) non progressor (NP) and progressor (P)
patients, and healthy controls (HC).
doi:10.1371/journal.pone.0099006.g002
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the intestinal level, further analyses were carried out only on 16S
rRNA data. The differences (P,0.05) in the relative abundance of
OTU associated with the NP, P or HC subjects are described in
Table 3. Within Firmicutes, all the 9 families showed at least one
species that statistically (P,0.05) differed between NP, P or HC.
Similar trends were found for the other three main phyla.
Free amino acids (FAA) profiling of feces
The highest (P,0.05) level of total FAA was found in the fecal
samples of P patients (3781 vs. 3124 and 2520 mg/kg for P vs. NP
and HC, respectively). As shown in Figure 6, Glu, Ala, Asp, Val,
Leu and Pro were the dominant FAA. Fecal samples of HC
contained the highest concentration of Cys and Lys (128 and
39 mg/kg, respectively). Besides, GABA, which is synthesized
through decarboxylation of Glu, was found at the highest
concentration in the fecal samples of NP patients (8.52 vs. 5.72
and 5.69 mg/kg of feces for NP vs. P and HC, respectively). a-
Ketoglutaric acid was present at the lowest level in the fecal
samples of P patients (179 mg/kg). The concentration of ammonia
(NH3) ranged from 98 (P) to 80 (HC) g/kg of fecal samples (data
not shown).
Volatile organic compounds (VOC) profiling of feces and
urines
VOC were identified from fecal (74 compounds) and urine (73
compounds) samples, and grouped according to chemical classes:
alcohols (10 and 15 compounds were identified from feces and
urine, respectively), aldehydes (7 and 10), esters (22 and 4),
aromatic heterocyclic (5 and 4), hydrocarbons (14 and 16), ketones
(8 and 16), short and medium chain fatty acids (SCFA) (5 and 4),
sulfur compounds (2 and 2) and terpens (1 and 2) (Table S1).
Overall, the content of the various metabolites largely varied
within the same group. Compared to HC, some compounds (ethyl
alcohol, 2,6-octadien-1-ol 3,7 dimethyl- (Z), 1-octanol, 4-methyl-
phenol and phenol 4-(1,1,3,3-tetramethylbutyl) were found at
significantly (P,0.05) higher levels in the feces and/or urines of
NP and, especially, P patients. Within aldehydes, tridecanal
showed the highest level in the fecal samples of HC (Table S1).
Nonanal, benzaldehyde and heptanal were found at the highest
levels in the urine samples of NP patients. Except for pentanoic
acid methyl ester, heptanoic acid 1, 1-dimethylethyl ester, hexyl n-
valerate, heptanoic acid 1-methylethyl ester, benzoic acid
hexadecyl ester, and phthalic acid methyl neopentyl ester, the
levels of esters were significantly (P,0.05) higher in the fecal
samples of NP and P than in those from HC (Table S1). Within
urine samples, ethyl acetate and phthalic acid methyl neopentyl
ester were at the highest levels in P and HC, respectively.
Aromatic heterocyclic were variously distributed within groups.
Except for benzene 1,4-bis(1, 1-dimethylethyl), hydrocarbons
showed higher levels in the fecal samples of NP patients with
respect to HC (Table S1). Compared to HC, hydrocarbons were
also significantly (P,0.05) higher in the urine samples of P
patients. The levels of ketons were significantly (P,0.05) lower in
the fecal samples of HC compared to those found in NP and,
especially, P patients (Table S1). Compared to HC, SCFA (acetic,
propanoic, butanoic and pentanoic acids) were significantly (P,
0.05) higher in the fecal samples of NP and P patients (Table S1).
Carbon disulfide showed the highest concentration in the fecal
samples of HC, while sulfur compounds were variously distributed
within in the urine samples of the three groups (Table S1). GC-
MS/SPME data were also analyzed by multivariate statistical
approaches (Canonical discriminant Analysis of Principal coordi-
nates, CAP and Principal Component Analysis, PCA). Both the
analyses showed a clear separation between the three groups of
subjects (See Figures 7A and 7B and data not shown).
Discussion
Various extra-intestinal non-communicable diseases are associ-
ated with the microbiota through intestinal immunity [18,47,48].
Nevertheless, to the best of our knowledge no data are available
regarding the composition of the intestinal microbiota of
immunoglobulin A nephropathy (IgAN) patients [49]. Recently,
a marked damage of the colonic epithelial barrier structure and an
alteration of the colonic microbiota were shown in humans and
Figure 3. Comparison of total and active bacterial phyla found in feces of subjects. Bacterial phyla distribution (%) found in fecal samples
of immunoglobulin A nephropathy (IgAN) non progressor (NP) and progressor (P) patients, and healthy controls (HC). The X-axis represents the
proportion of phyla from total (16S rDNA) and active (16S rRNA) bacteria.
doi:10.1371/journal.pone.0099006.g003
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Table 3. Immunoglobulin A nephropathy (IgAN) associated microbiome.
Phylum/Family Specie Avg (%) HC Avg (%) NP Avg (%) P
Firmicutes/Ruminococcaceae Ruminococcus flavefaciens 0.16a 0.18a 0.06b
Ruminococcus gnavus 0.48a 0.29a 0.15b
Ruminococcus obeum 0.07b 0.20a 0.11a
Anaerofilum sp. 0.13a 0.06b 0.11a
Oscillospira sp. 3.79a 2.56a,b 1.75b
Sporobacter termitidis 0.07b 0.17a 0.17a
Subdoligranulum sp. 0.30b 0.86a 0.51a,b
Anaerotruncus sp. 0.02b 0.07a 0.06a
Ethanoligenens harbinense 0.03b 0.21a 0.03b
Hydrogenoanaerobacterium saccharovorans 0.04b 0.14a 0.04b
Papillibacter cinnamivorans 0.03b 0.08a,b 0.13a
Firmicutes/Clostridiaceae Clostridium aminophilum 0.93a,b 0.72b 1.36a
Clostridium bolteae 0.51b 1.25a 0.78a,b
Clostridium clostridioforme 0.59a 0.22b 0.24b
Clostridium herbivorans 0.12b 0.25a 0.24a
Clostridium methylpentosum 0.49a 0.43a 0.13b
Clostridium nexile 0.48a,b 0.68a 0.23b
Clostridium symbiosum 0.37a 0.32a 0.22a,b
Clostridium xylanolyticum 0.05b 0.12a 0.12a
Firmicutes/Lachnospiraceae Roseburia faecis 0.84c 1.86b 3.31a
Roseburia intestinalis 0.59b 4.12a 0.49b
Roseburia inulinivorans 0.15b 0.22a,b 0.38a
Dorea sp. 0.90a,b 1.24a 1.13a
Coprococcus eutactus 0.88a 0.44b 0.24c
Coprococcus sp. 0.32a 0.13b 0.33a
Lachnospira pectinoschiza 1.01a 0.84a,b 0.54b
Butyrivibrio crossotus 0.30c 2.34a 0.78b
Firmicutes/Eubacteriaceae Eubacterium desmolans 0.05b 0.09a 0.10a
Eubacterium eligens 1.04a 0.68a,b 0.45b
Eubacterium oxidoreducens 0.22a 0.04c 0.07b
Eubacterium ramulus 0.14a,b 0.20a 0.10b
Eubacterium siraeum 0.99a 0.28b 0.22b
Eubacterium sp. 5.81b 5.96b 8.57a
Firmicutes/Lactobacillaceae Lactobacillus rogosae 0.20b 0.43a 0.19b
Lactobacillus sp. 0.23a 0.00b 0.00b
Firmicutes/Streptococcaceae Streptococcus salivarius 0.03b 0.01b 0.10a
Streptococcus sp. 0.05b 0.05b 0.15a
Firmicutes/Erysipelotrichaceae Catenibacterium sp. 0.37a 0.16b 0.22a,b
Eubacterium biforme 0.14a 0.01b 0.00b
Turicibacter sp. 0.01c 0.11a 0.04b
Firmicutes/Peptococcaceae Desulfotomaculum sp. 0.30a,b 0.42a 0.20b
Firmicutes/Veillonellaceae Dialister sp. 0.38a 0.18b 0.26a,b
Phascolarctobacterium sp. 0.24a 0.14a,b 0.10b
Bacteroidetes/Bacteroidaceae Bacteroides coprocola 1.67b,c 4.07a 2.21b
Bacteroides faecis 0.17b 0.28a,b 0.41a
Bacteroides finegoldii 0.23a 0.03c 0.10b
Bacteroides fragilis 0.10a 0.13a 0.04b
Bacteroides intestinalis 0.15a 0.00b 0.15a
Bacteroides ovatus 0.25a 0.11b 0.18a,b
Bacteroides plebeius 1.18a 0.27b 1.79a
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animals with advanced chronic kidney disease (CKD)
[28,32,50,51]. The present study showed, for the first time, that
some traits of the gut microbiota significantly varied between
IgAN non-progressors (NP) and progressors (P) patients and
healthy controls (HC). Moreover, it was showed that urinary and
fecal metabolomic profiles, differed between study groups.
As determined by culture-dependent methods, cell densities of
the total and anaerobe bacteria decreased in the fecal samples of
NP and, especially, P patients. The lowest levels of presumptive
Clostridium, Enterococcus, Lactobacillus, Leuconostoc and Bifidobacterium
were found in the fecal samples of NP and, especially in P.
The fecal microbiota was further studied by culture-indepen-
dent methods. According to previous results on induced chronic
renal failure (CRF) rats [28], the fecal microbial diversity
decreased in NP and, especially, in P patients. Overall, a similar
trend was also found in IBD and allergic patients [52,53]. This
study showed that the composition of the main bacterial phyla
(Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria)
significantly differed in the fecal microbiota of NP, P and HC
subjects.
Primer selection can influence the profile of a community
generated by sequencing but the level of this bias on deep-
sequencing methodologies is not well elucidated. While several
investigations suggest that V1-V3 regions overestimate species
richness, others support the use of these regions for deep
sequencing [34,42,45]. As shown by multivariate statistical
analyses, the main differences between NP, P and HC were
concerning metabolically active bacteria (16S rRNA data).
Regarding total bacteria, the main difference was found for the
Streptoccocaceae family. The highest percentage of 16S rDNA
reads belonging to Streptococcaeae was found in P patients. Using
16S rRNA, the number of Streptococcaeae reads decreased. This
might be related to the survival during the gastrointestinal transit.
A link between tonsillar infection caused by some salivary bacteria,
including Streptococcus sp., and IgAN was hypothesized [54].
Besides, streptococcal proteins (e.g., M and GroEL) were present
in tissues or they were recognized by sera of IgAN patients [55,56].
Based on metabolically active bacteria (16S rRNA data),
Firmicutes increased in the fecal samples of NP and, especially,
P patients. The ratio between Firmicutes/Bacteroidetes may
dramatically change by antibiotics, dietary nutrients and/or
diseases [18]. The increase of Firmicutes was mainly related to
the highest percentages of some genera/species of Lachnospir-
aceae (Roseburia faecis, Dorea sp., Butyrivibrio crossotus) and Eubacter-
iaceae (Eubacterium sp.). The Lachnospiraceae family also increased
in induced CRF rats [28]. According to the results from culture-
dependent methods, Enterococcus and Lactobacillus were found at the
highest levels in HC. Overall, Lactobacillus is the main probiotic
Table 3. Cont.
Phylum/Family Specie Avg (%) HC Avg (%) NP Avg (%) P
Bacteroides salyersiae 0.05b 0.03b 0.23a
Bacteroides sp. 17.54a 13.59a 14.32a
Bacteroides thetaiotaomicron 0.10a 0.07a,b 0.05b
Bacteroides uniformis 2.24a 0.52b 0.75b
Bacteroides vulgatus 3.29a 3.28a 1.40b
Pseudoflavonifractor capillosus 0.07b 0.08b 0.16a
Bacteroidetes/Porphyromonadaceae Barnesiella intestinihominis 0.29a,b 0.16b 0.45a
Butyricimonas virosa 0.15a 0.03c 0.07b
Parabacteroides distasonis 0.21b,c 0.84a 0.37b
Bacteroidetes/Prevotellaceae Prevotella copri 1.80a 0.96a,b 1.13a
Prevotella sp. 2.35a 0.61b 2.06a
Bacteroidetes/Rikenellaceae Alistipes putredinis 1.67a 0.89a,b 1.12a
Alistipes sp. 0.27a 0.16a 0.17a
Proteobacteria/Rhodospirillaceae Rhodospirillum rubrum 0.08a 0.01b 0.12a
Rhodospirillum sp. 0.17a 0.01c 0.05b
Thalassospira sp. 0.03b 0.02b 0.06a
Proteobacteria/Alcaligenaceae Sutterella sp. 0.23b 0.54a 0.57a
Proteobacteria/Sutterellaceae Parasutterella excrementihominis 0.03b 0.17a 0.17a
Proteobacteria/Enterobacteriaceae Escherichia coli 0.02b 0.07a,b 0.12a
Escherichia sp. 0.02c 0.04b 0.15a
Proteus sp. 0.29b 0.86a 0.30b
Shigella sp. 0.01b 0.01b 0.15a
Enterobacter sp. 0.01b 0.08a 0.11a
Actinobacteria/Bifidobacteriaceae Bifidobacterium sp. 2.59a 1.21b 0.11c
Actinobacteria/Coriobacteriaceae Collinsella aerofaciens 0.14b 0.48a 0.15b
Relative proportions of predominant metabolically active bacteria (16S rRNA) showing significant (P,0.05) differences between fecal samples of healthy controls (HC),
non progressor (NP) and IgAN progressor (P).
a–cValues within a row with different superscript letters are significantly different (P,0.05).
doi:10.1371/journal.pone.0099006.t003
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genus within lactic acid bacteria. The composition of Bacteroida-
ceae, Porphyromonadaceae, Prevotellaceae and Rikenellaceae
families differed among NP, P and HC subjects. Nevertheless,
Bacteroides fragilis group, which synthesizes lipopolysaccharide (LPS)
as an important bacterial virulence factor [42], did not increase in
the fecal samples of NP and/or P patients. According to a previous
report on CRF or ESRD patients [28,57], the level of
Sutterellaceae and Enterobacteriaceae species (LPS producing
bacteria) were almost the highest in the fecal samples of NP and/
or P patients. In addition, DNA from Enterobacter, Escherichia and
Proteus species was found in the blood of ESRD patients [58]. The
content of Bifidobacterium species decreased in the fecal samples of
NP and, especially, P patients. Bifidobacterium species were
demonstrated to have species- and strain-specific influence on
immunity [59]). Various species of Bifidobacterium synthesize exo-
polysaccharides, which act as fermentable substrates for human
intestinal bacteria [60].
As shown by metagenomic studies, the intestinal microbiota is
directly involved on the metabolism of proteins, FAA and
carbohydrates [18]. Overall, metabolites produced by intestinal
microbes play a direct role in health and disease [61,62]). A very
few studies considered the metabolome of IgAN patients and no
reports are available for human fecal samples [49,63]. Previously,
it was shown that serum samples of IgAN patients had an altered
level of some metabolites, including an increase of some FAA (e.g.,
Asp, Glu, Gly, Ala, Val, Met, Ile, Leu, Tyr, Phe and Pro) [49,50].
Compared to HC, a marked increase of total FAA was found in
the fecal samples of NP and, especially, P patients. It was
hypothesized that the IgAN pathology causes a marked alteration
of the Krebs cycle and the increased hydrolysis of proteins from
cell necrosis, which affects the level of FAA in serum. The
absorption of proteins seems to be decreased in CRF patients, thus
increasing the amount of proteins that are available for microbial
proteolysis [64]. An alteration of the fecal microbiota composition,
which was related to an increased level of FAA, was described in
colon carcinoma patients [65].
The highest level of alcohols was found in the fecal samples of P
patients. 4-Methyl-phenol (p-cresol) seemed to be over-synthesized
in IgAN patients. High level of p-cresol and p-cresyl sulfate, which
derive from the microbial hydrolysis of tyrosine, were associated
with ESRD and CKD [66]. Highest levels of alcohols were also
found in CD children [23,24]. A positive correlation was found
between the synthesis of alcohols by intestinal bacteria and
endotoxemia [67]. Besides, some long-chain aliphatic alcohols
(C6–C20) may inhibit the growth of various bacteria [68].
Compared to HC, the lowest level of aldehydes was found in
Figure 4. Principal component analysis (PCA) of total bacterial genera found in feces of subjects. Score plot of the three principal
components (PC) after principal component analysis (PCA) of total bacterial genera (16S rDNA), which were found in the fecal samples of
immunoglobulin A nephropathy (IgAN) non progressor (NP) and progressor (P) patients, and healthy controls (HC). 1–16, number of fecal samples for
each group of subjects.
doi:10.1371/journal.pone.0099006.g004
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Figure 5. Principal component analysis (PCA) of active bacterial genera found in feces of subjects. Score plot of the three principal
components (PC) after principal component analysis (PCA) of metabolically active bacterial genera (16S rRNA), which were found in the fecal samples
of immunoglobulin A nephropathy (IgAN) non progressor (NP) and progressor (P) patients, and healthy controls (HC). 1–16, number of fecal samples
for each group of subjects.
doi:10.1371/journal.pone.0099006.g005
Figure 6. Fecal levels of free amino acids (FAA) in subjects. Concentration (mg/kg) of individual free amino acids (FAA) found in the fecal
samples of immunoglobulin A nephropathy (IgAN) non progressor (NP) and progressor (P) patients, and healthy controls (HC). Data are the means of
three independent experiments and standard deviations, performed in duplicate (n = 6).
doi:10.1371/journal.pone.0099006.g006
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Figure 7. Principal component analysis (PCA) of volatile organic metabolites found in feces of subjects. Score plots of the two principal
components (PC) after principal component analysis (PCA) of volatile organic metabolites of the fecal (A) and urine (B) samples of immunoglobulin A
nephropathy (IgAN) non progressor (NP) and progressor (P) patients, and healthy controls (HC).
doi:10.1371/journal.pone.0099006.g007
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the fecal and urine samples of P patients. On the contrary, urine
samples of NP patients showed the highest level of aldehydes.
Based on these findings, different catabolic pathways for FAA may
be suggested for the subjects of study. Furthermore, the level of
esters and ketons strongly increased in the fecal samples of NP and
P patients. No previous data are available for IgAN, CKD and
ESRD patients. Esterification reactions at the colon level are
considered like a microbial strategy to remove toxic compounds
[69]. The conversion of fatty acids into ketons and glucose
increased in the hepatic cells to supply energy for peripheral cells,
which are unable to transport glucose in the absence of insulin
[22]. This hypothesis was also supported through the increase of
SCFA (e.g., acetic acid), which represent the end products of the
lipid metabolism [49]. Compared to fecal samples of HC, NP and
P patients showed significantly higher levels of total SCFA (acetic,
propanoic, butanoic and pentanoic acids).
IgAN patients had an altered fecal microbiota and VOC
profiling, which in part differed between NP and P. The fecal
microbiota and the FAA and VOC profiling of NP were more
similar to HC than those of P patients. Dietary implementation
with prebiotics and/or probiotic could be a useful tool to restore
some microbial gaps (e.g., lactobacilli and bifidobacteria). Since
this is a transversal study, further investigations are necessary to
highlight the exact relationships between some microbial groups
and IgAN.
Supporting Information
Figure S1 Total and active bacteria found in feces of
subjects. Relative abundance (%) of total (16S rDNA) (A) and
metabolically active (16S rRNA) (B) Firmicutes, Bacteroidetes,
Proteobacteria and Actinobacteria and related families, which
were found in the fecal samples of immunoglobulin A nephropathy
(IgAN) non progressor (NP) and progressor (P) patients, and
healthy controls (HC).
(TIF)
Figure S2 Permutation analysis. Permutation analysis of the
total (16S rDNA) and metabolically active (16S rRNA) bacterial
families composition found in fecal samples of immunoglobulin A
nephropathy (IgAN) non progressor (NP) and progressor (P)
patients, and healthy controls (HC).
(TIF)
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